Mode
Text Size
Log in / Sign up
N/A N=26 Randomized Quadruple-blind Treatment

Remotely Supervised tDCS for Persistent Post-traumatic Headache

Persistent Post Traumatic Headache · Mild Traumatic Brain Injury

Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Apr 2023
Primary outcome: Primary: Change From Baseline in the Number of Moderate-to-Severe Headache Days Per Month — -2.5; 2.3; -3.9; 1.2 Days per Month

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
transcranial direct current stimulation (Device)
Age
Adult · 20+ yrs
Sex
All
Sponsor
VA Office of Research and Development
Primary completion
Mar 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in the Number of Moderate-to-Severe Headache Days Per Month
-2.5; 2.3; -3.9; 1.2
SECONDARY
Change From Baseline in the Total Number of Headache Days Per Month
-4.0; 1.54; 2.1; -0.2
SECONDARY
Change From Baseline in the Quality of Life Based on Change in Headache Impact Test-6 (HIT-6)
-4.5; -4.0; 0.8; -5.4
SECONDARY
Change From Baseline in the Acute Pain Medication Days Per Month
-2.7; -0.4; 3.0; -2.3
SECONDARY
Number of Participants With a 50% Reduction in Headache Frequency
1; 0; 9; 11; 2; 0
SECONDARY
Change From Baseline in Scores on the Patient Health Questionnaire (PHQ-9)
-0.6; 0.1; 0.1; -1.0
SECONDARY
Change From Baseline in Scores on the DSM-5 PTSD Checklist (PCL-5)
2.9; 1.9; -1.4; -1.5
SECONDARY
Change From Baseline in Scores on the Beck's Anxiety Inventory (BAI)
-3.2; 1.9; -2.8; 3.5
SECONDARY
Change From Baseline in Scores on the Rivermead Post-Concussion Questionnaire (RPQ)
-10.2; -4.2; -4.8; -4.0
SECONDARY
Change From Baseline in Scores on the Insomnia Severity Index (ISI)
-0.5; 0.2; -0.5; 0.9

Summary

This pilot study is designed to provide preliminary data for a large scale, randomized clinical trial to evaluate the efficacy of remotely administrated at home transcranial Direct Current Stimulation (tDCS) with real-time monitoring via VA Tele-health for persistent post traumatic headache associated with mild traumatic brain injury (mTBI). Participants will receive total of 20 sessions of tDCS over four weeks. The investigators anticipate that the results generated from the study will directly translate into immediate meaningful clinical application: not only in management of chronic post traumatic headache, but also in reduction of acute pain medication use, and improving quality of life for our veterans with this debilitating neurological disorder.

Eligibility Criteria

Inclusion Criteria

  • Verified history of mTBI
  • Persistent PTH as defined by International Classification of Headache Disorders (ICHD) III diagnostic criteria("Headache Classification Committee of the International Headache Society (IHS) The ICHD, 3rd Edition 2018).
  • Verification of headache frequency through prospectively collected baseline information during the 28-day screening/baseline phase.
  • Not currently taking a migraine or headache preventive medication OR has been taking a stable dose of a preventive for at least 60 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period.
  • The investigators will include medication overuse headache as defined by ICHD III diagnostic criteria.
  • Participants is either not of childbearing potential, or if they are of childbearing potential, they agree either to remain abstinent or use (or have their partner use) an acceptable method of birth control for the duration of the study.
  • Male or female, age between 20-60 who demonstrates compliance with the electronic Daily Headache Diary during the 28-day baseline phase as defined by entry of headache data on a minimum of 22 to 28 days (80% diary compliance).

Exclusion Criteria

  • Unable to complete headache diary as required by protocol.
  • Any psychiatric condition with psychotic features, and/or any other psychiatric disorder not stable or well controlled, that would interfere in the ability to complete study activities
  • Received onabotulinumtoxinA, cognitive behavior therapy, physical therapy or any other form of non-pharmacological therapy for headaches during the 4 months before screening.
  • Has a planned military deployment within the 6 months post screening.
  • Active substance abuse within last 4 months.
  • History of seizure, stroke, multiple sclerosis or other unstable neurological condition or a significant abnormal neurological examination.
  • Unable to tolerate tDCS stimulation.
  • Have any other conditions that in the judgment of the Investigator would make the participants unsuitable for inclusion or interfere with participating or completing the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04012853). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search